Edward F. Kreider

TL;DR: The results demonstrate the safety and activity of 10-1074 in humans and support the idea that antibodies targeting the V3 glycan supersite might be useful for the treatment and prevention of HIV-1 infection.

TL;DR: It is concluded that administration of 3BNC117 exerts strong selective pressure on HIV-1 emerging from latent reservoirs during ATI in humans, suggesting failure to escape over a period of 9-19 weeks.

TL;DR: Analyses of virus populations before ART as well as before and after ART interruption showed that VRC01 exerted pressure on rebounding virus, resulting in restriction of recrudescent viruses and selection for preexisting and emerging antibody neutralization-resistant virus.

TL;DR: HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals and enhances host humoral immunity to HIV-1, and neutralizing antibodies may be a promising therapy for HIV- 1 because of their potential to reduce the viral reservoir.

TL;DR: By studying the cooperation among multiple V3-glycan B cell lineages and their coevolution with autologous virus throughout 5 years of infection, key events are identified in the ontogeny of a V3 -glycan bnAb lineage.